Bebetter Med

About Bebetter Med

Bebetter Med, established in Guangzhou, China in 2012 by founder Dr. Changgeng Qian, operates as a biopharmaceutical firm centered on creating innovative drugs. The company directs its efforts towards significant disease areas, including oncology, autoimmune diseases, and metabolic disorders. Dr. Qian, who previously held the role of senior vice president at Curis in the US, has a background in discovering novel anti-cancer compounds, notably contributing to the development of Erivedge, a drug for basal cell carcinoma. This experience in the U.S. biopharmaceutical sector, including time at Millennium Pharmaceuticals, shaped the foundation of Bebetter Med upon his return to China.

The company's business model is rooted in the independent research and development of first-in-class small molecule and oligonucleotide drugs. Bebetter Med focuses on the entire drug development pipeline, from initial target discovery and molecular design to preclinical and clinical trials, and finally, new drug registration. Its revenue generation is anticipated from the commercialization of its drug candidates upon regulatory approval. The company operates through its main entity in China and a U.S. subsidiary, BeBetter Pharma, which concentrates on siRNA therapeutics. This dual structure allows for strategic international collaborations to accelerate development and commercialization. For instance, a 2013 agreement with PharmaEngine granted the Taiwanese company exclusive worldwide manufacturing, development, and commercialization rights for certain drug candidates, excluding Greater China, where Bebetter retains the rights.

Bebetter Med's product pipeline is extensive, with 11 Class I new drug projects. A key candidate is BEBT-908, a dual PI3K/HDAC inhibitor, for which a New Drug Application (NDA) was accepted in China in October 2023 for treating relapsed or refractory diffuse large B-cell lymphoma. Another significant product, BEBT-109, a pan-mutant EGFR inhibitor, received approval for Phase III clinical trials. The company has also developed proprietary siRNA delivery platforms, including Peptide-Oligonucleotide Conjugates (POCs) and GalNAc Dual Oligonucleotide Conjugates (GDOCs), to address unmet medical needs. In May 2020, the company secured $28.05 million in a Series A funding round. A major milestone was reached in December 2021 when it was restructured from a limited liability company to a joint-stock company, signaling its preparation for a new phase of development, including a planned IPO.